Efficacy and safety of efdamrofusp alfa versus aflibercept in participants with neovascular age-related macular degeneration: a randomized, double-masked, active-controlled, non-inferiority, phase 2 trial
Junran Sun,Yanping Song,Yuanyuan Gong,Liming Tao,Hong Wang,Xiangwen Shu,Ying Wen,Ling Cui,Jian Ye,Shujie Lu,Junjie Deng,Haoyu Li,Yihua Xu,Lei Qian,Zhifeng Wu,Yanlong Bi,Qinghuai Liu,Xiangzhong Xu,Miaoqin Wu,Jinglin Zhang,Jilong Hao,Jianping Tong,Hong Dai,Feng Wang,MingWei Zhao,Junfeng Mao,Chaopeng Li,Tao He,Cheng Pei,Xiaoling Liu,Xian Wang,Mingxin Li,Wei Wang,Qinxiang Zheng,Huaijin Guan,Hui Peng,Ke Fan,Wenfang Zhang,Dan Zhu,Songping Yu,Wenbin Wei,Lin Ding,Jinying Li,Peirong Lu,Ming Yan,Wei Liu,Huixun Jia,Xiaodong Sun
DOI: https://doi.org/10.1016/j.oret.2024.08.014
2024-08-28
Abstract:Purpose: To evaluate efficacy and safety of efdamrofusp alfa compared with aflibercept in neovascular age-related macular degeneration (nAMD). Design: Randomized, double-masked, multicenter, active-controlled, non-inferiority phase 2 study PARTICIPANTS: A total of 231 treatment-naïve and previously treated participants with active choroidal neovascularization secondary to nAMD were enrolled. Methods: Eligible participants were randomized (1:1:1) to 2 mg efdamrofusp alfa, 4 mg efdamrofusp alfa or 2 mg aflibercept groups. Participants in all groups received three initial monthly loading doses, followed by treatment every 8 weeks with assessment every 4 weeks up to week 52. Main outcome measures: The primary endpoint was the mean BCVA change from baseline to week 36. The pre-specified noninferiority margin was set as -5 letters (80% CI). Results: Each treatment group included 77 participants. The mean BCVA changes from baseline to week 36 for 2 mg efdamrofusp alfa, 4 mg efdamrofusp alfa and aflibercept groups were +10.6, +11.4, +12.0 letters, respectively; Least Squares (LS) mean difference were -1.4 (80% CI: -3.5 to 0.7) between 2 mg efdamrofusp alfa and aflibercept, and -0.6 (80% CI: -2.7 to 1.6) between 4 mg efdamrofusp alfa and aflibercept. Mean central retinal thickness changes were consistent across groups. Adverse event rate was comparable among the groups. Conclusions: Efdamrofusp alfa demonstrated noninferiority to aflibercept in BCVA improvement, accompanied by a similar safety profile.